Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 223

1.

Imaging-guided biopsy of (18)F-FDG-avid extrapulmonary lesions: do lesion location and morphologic features on CT affect the positive predictive value for malignancy?

Nguyen ML, Gervais DA, Blake MA, Mueller PR, Sahani DV, Hahn PF, Uppot RN.

AJR Am J Roentgenol. 2013 Aug;201(2):433-8. doi: 10.2214/AJR.12.9166.

PMID:
23883226
2.
3.

False-Positive [18F]fluorodeoxyglucose-avid lymph nodes on positron emission tomography-computed tomography after allogeneic but not autologous stem-cell transplantation in patients with lymphoma.

Ulaner GA, Lilienstein J, Gönen M, Maragulia J, Moskowitz CH, Zelenetz AD.

J Clin Oncol. 2014 Jan 1;32(1):51-6. doi: 10.1200/JCO.2013.50.8044. Epub 2013 Nov 18.

PMID:
24248697
4.

Detection of bone metastases: assessment of integrated FDG PET/CT imaging.

Taira AV, Herfkens RJ, Gambhir SS, Quon A.

Radiology. 2007 Apr;243(1):204-11.

PMID:
17392254
5.

Solid splenic masses: evaluation with 18F-FDG PET/CT.

Metser U, Miller E, Kessler A, Lerman H, Lievshitz G, Oren R, Even-Sapir E.

J Nucl Med. 2005 Jan;46(1):52-9.

6.

Malignancy rate of biopsied suspicious bone lesions identified on FDG PET/CT.

Adams HJ, de Klerk JM, Heggelman BG, Dubois SV, Kwee TC.

Eur J Nucl Med Mol Imaging. 2016 Jul;43(7):1231-8. doi: 10.1007/s00259-015-3282-4. Epub 2016 Jan 4.

7.

Dual-tracer PET/CT imaging in evaluation of metastatic hepatocellular carcinoma.

Ho CL, Chen S, Yeung DW, Cheng TK.

J Nucl Med. 2007 Jun;48(6):902-9. Epub 2007 May 15.

8.

Feasibility of a multimodal (18)F-FDG-directed lymph node surgical excisional biopsy approach for appropriate diagnostic tissue sampling in patients with suspected lymphoma.

Povoski SP, Hall NC, Murrey DA Jr, Wright CL, Martin EW Jr.

BMC Cancer. 2015 May 8;15:378. doi: 10.1186/s12885-015-1381-z.

9.

Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.

Seo MJ, Lee JJ, Kim HO, Chae SY, Park SH, Ryu JS, Ahn SH, Lee JW, Son BH, Gong GY, Moon DH.

Eur J Nucl Med Mol Imaging. 2014 Mar;41(3):438-45. doi: 10.1007/s00259-013-2600-y. Epub 2013 Nov 6.

PMID:
24196918
10.

Diagnostic value of FDG-PET/CT for lymph node metastasis of colorectal cancer.

Kwak JY, Kim JS, Kim HJ, Ha HK, Yu CS, Kim JC.

World J Surg. 2012 Aug;36(8):1898-905. doi: 10.1007/s00268-012-1575-3.

PMID:
22526032
11.

Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities.

Cornelis F, Silk M, Schoder H, Takaki H, Durack JC, Erinjeri JP, Sofocleous CT, Siegelbaum RH, Maybody M, Solomon SB.

Eur J Nucl Med Mol Imaging. 2014 Dec;41(12):2265-72. doi: 10.1007/s00259-014-2852-1. Epub 2014 Aug 9.

PMID:
25106463
12.

Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?

Schaefer NG, Taverna C, Strobel K, Wastl C, Kurrer M, Hany TF.

Radiology. 2007 Jul;244(1):257-62.

PMID:
17581905
13.

Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.

Santhosh S, Mittal BR, Bhasin D, Srinivasan R, Rana S, Das A, Nada R, Bhattacharya A, Gupta R, Kapoor R.

J Gastroenterol Hepatol. 2013 Feb;28(2):255-61. doi: 10.1111/jgh.12068.

PMID:
23278193
14.

Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.

Suga K, Kawakami Y, Hiyama A, Sugi K, Okabe K, Matsumoto T, Ueda K, Tanaka N, Matsunaga N.

Ann Nucl Med. 2009 Aug;23(6):523-31. doi: 10.1007/s12149-009-0268-y. Epub 2009 May 15.

PMID:
19444550
15.

Comparison of the diagnostic value of FDG-PET/CT and axillary ultrasound for the detection of lymph node metastases in breast cancer patients.

Riegger C, Koeninger A, Hartung V, Otterbach F, Kimmig R, Forsting M, Bockisch A, Antoch G, Heusner TA.

Acta Radiol. 2012 Dec 1;53(10):1092-8. doi: 10.1258/ar.2012.110635. Epub 2012 Sep 22.

PMID:
23002144
16.

Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?

Cuellar SL, Carter BW, Macapinlac HA, Ajani JA, Komaki R, Welsh JW, Lee JH, Swisher SG, Correa AM, Erasmus JJ, Hofstetter WL.

J Thorac Oncol. 2014 Aug;9(8):1202-6. doi: 10.1097/JTO.0000000000000222.

17.

Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.

Nakajo M, Nakajo M, Jinguji M, Tani A, Kajiya Y, Tanabe H, Fukukura Y, Nakabeppu Y, Koriyama C.

Radiology. 2013 Jun;267(3):891-901. doi: 10.1148/radiol.13121546. Epub 2013 Mar 6.

PMID:
23468571
18.

Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.

Eiber M, Takei T, Souvatzoglou M, Mayerhoefer ME, Fürst S, Gaertner FC, Loeffelbein DJ, Rummeny EJ, Ziegler SI, Schwaiger M, Beer AJ.

J Nucl Med. 2014 Feb;55(2):191-7. doi: 10.2967/jnumed.113.123646. Epub 2013 Dec 5.

20.

Colonoscopic Findings in Patients With Incidental Colonic Focal FDG Uptake.

Keyzer C, Dhaene B, Blocklet D, De Maertelaer V, Goldman S, Gevenois PA.

AJR Am J Roentgenol. 2015 May;204(5):W586-91. doi: 10.2214/AJR.14.12817.

PMID:
25905966

Supplemental Content

Support Center